AUTHOR=Taguchi Takashi , Koh Ronald , Takawira Catherine , Rademacher Nathalie , Gilad Gad M. , Aronson Randy D. , Lopez Mandi J. 

TITLE=Agmatine for Pain Management in Dogs With Coxofemoral Joint Osteoarthritis: A Pilot Study

JOURNAL=Frontiers in Veterinary Science

VOLUME=5

YEAR=2018

URL=https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2018.00311

DOI=10.3389/fvets.2018.00311

ISSN=2297-1769

ABSTRACT=<p><bold>Background:</bold> Pain from coxofemoral joint (CFJ) osteoarthritis (OA) characteristic of canine hip dysplasia (CHD) afflicts many dogs. Intervertebral disc (IVD) degeneration is a common CFJ OA comorbidity. Non-steroidal anti-inflammatory drug (NSAID) administration is standard for treatment of pain from degenerative joint disease. Potential side effects and tolerance from prolonged administration drive efforts to identify compounds that may be alternatives to or combined with NSAIDs. Agmatine, decarboxylated arginine, reportedly alleviates neuropathic pain, a likely component of OA pain. The objective of this study was to compare treatment response to agmatine and carprofen in dogs with varying degrees of CFJ OA with or without IVD degeneration and to test the hypothesis that agmatine improves hindlimb use comparably to carprofen and more than placebo.</p><p><bold>Methods:</bold> Nine hound-type dogs received oral carprofen (4.4 mg/kg, sid) for 7 days. Six months later, oral agmatine sulfate (25 mg/kg, bid) or placebo (hydroxypropyl methylcellulose, bid) was administered to the same dogs for 28 days with a 2 week washout period between treatments. Validated pain assessment scores were measured before treatment and every seven days throughout the treatment periods. Serum chemistry levels and ground reaction forces (GRF) were quantified before and after each treatment period. A board-certified radiologist quantified radiographic CFJ OA based on Orthopedic Foundation for Animals criteria and IVD degeneration on magnetic resonance images. GRFs were compared among treatments at each time point and among time points for each treatment.</p><p><bold>Results:</bold> There were no detectable adverse effects with any treatment. Significant results included improved GRFs in dogs with mild CFJ OA (<italic>N</italic> = 3) following agmatine administration compared to carprofen or placebo and a trend for improved GRFs in dogs with moderate CFJ OA (<italic>N</italic> = 2) following carprofen vs. agmatine or placebo. Neither agmatine nor carprofen improved GRFs in dogs with severe CFJ OA (<italic>N</italic> = 4). The GRFs improved in dogs with IVD degeneration (<italic>N</italic> = 3) following carprofen treatment compared to agmatine or placebo regardless of CFJ OA score, but no effect was observed in dogs with normal lumbar spines (<italic>N</italic> = 6).</p><p><bold>Conclusions:</bold> Results support agmatine over carprofen treatment to improve limb use in dogs with early or mild CFJ OA, while carprofen may be the better choice for dogs with moderate CFJ OA or IVD degeneration regardless of CFJ OA severity.</p>